**Prevalence of Multidrug Resistant *Acinetobacter baumannii* in Eight Tertiary Hospitals in Southwestern Nigeria**

Ike WE1, Adeniyi BA1\*, Soge OO2

1Department of Pharmaceutical Microbiology, University of Ibadan, Ibadan, Nigeria.

2Department of Global Health, University of Washington, Seattle, USA.

[baadeniyi@yahoo.co.uk](mailto:baadeniyi@yahoo.co.uk)

**Abstract:** The genus *Acinetobacter* currently contains 34 species, the vast majority of which are not regularly implicated in causing infection. However, incidences of hospital acquired infection with *Acinetobacter* species are increasing, mainly due to the rise in the number of infections caused by the species *Acinetobacter baumannii* in immune-compromised patients particularly in intensive care units (ICUs). The goal of this study is to investigate prevalence and resistance patterns of multidrug resistant *A.* baumannii strains isolated from clinical samples from tertiary hospitals in southwest Nigeria. The descriptive-cross sectional study was conducted in 8 major tertiary hospitals distributed within southwest Nigeria. Seventy-two strains of *A*.baumannii were isolated from clinical sources from April 2011 through May 2013. The identities of the isolates to species level were confirmed by standard biochemical methods using Oxoid Microbact™ Gram-negative identification system. The susceptibility patterns to 34 antimicrobial agents belonging to 13 classes of antibiotics were performed by disk diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Computer -aided Microbact software identified all the isolates as A. baumannii with each isolate been resistant to ≥3 classes of antibiotics. All theisolates were resistant to ≥14 antimicrobial agents tested, with 69 (95.8%) isolates resistant to 20-34 antimicrobial agents. All the isolates were also resistant to amoxicillin, amoxicillin-clavulanate, ampicillin, cefpodoxime, ceftazidime, ceftriaxone, cefuroxime, and cloxacillin. Significantly high rates of resistance were observed for erythromycin (98.6%); cephazolin (97.2%); aztreonam (93.1%); tetracycline (91.7%); cephalothin, trimethoprim-sulfamethoxazole (90.3%); kanamycin (88.5%); gentamicin, ticarcillin (86.1%); piperacillin, cefoxitin (87.5%), nitrofurantoin (81.9%); chloramphenicol (80.3%); ofloxacin (66.7%); and colistin (63.9%). High rates of carbapenem resistance were also recorded against meropenem (77.8%) and imipenem (56.9%). The least resistance was observed for azithromycin (37.9%); ciprofloxacin, polymyxin B (40.3%); and amikacin (43.1%). *A. baumannii* isolates from Southwest Nigeria showed unacceptably high rates of resistance to multiplicity of antimicrobial agents, including those not readily available in Nigeria. This study calls for a functional surveillance of *A. baumannii* antimicrobial resistance in Nigeria.

[Ike WE, Adeniyi BA, Soge OO. **Prevalence of Multidrug Resistant *Acinetobacter baumannii* in Eight Tertiary Hospitals in Southwestern Nigeria.** *N Y Sci J* 2014;7(11):86-93]. (ISSN: 1554-0200). <http://www.sciencepub.net/newyork>. 11

**Keywords:** Multidrug Resistant, *Acinetobacter baumannii*, Southwest Nigeria.

**Introduction:**

Multidrug-resistant *Acinetobacter* baumannii (MDRAB) have emerged as a substantial public health problem worldwide. Its clinical significance over the last 15 years has been propelled by its remarkable ability to up-regulate innate resistance mechanism and acquires new resistance determinants with ease; tolerate wide range of pH, salinity, humidity, and unique ability to survive on almost all nutrient sources (Bergogne-BereZin and Towner, 1996). These abilities have allowed this pathogen to be ubiquitous in the hospital environment as well as the community and have made it one of the frontline pathogens threatening the current antibiotic era (Falagas and Karveli, 2007b). Also, the ability of A. baumannii to form biofilms has been reported to play a role in the process of colonization (Rajamohan et al., 2009). As such, *A. baumannii* has become a frequent colonizer of respiratory and digestive tracts, skin and throat (Rajamohan *et al*., 2009). Biofilms help the bacteria resist disinfection, allowing the participating cells to trade resistance genes, while facilitating the persistence of the pathogen (Rajamohan *et al*., 2009).

MDR *A. baumannii* have been reported to cause infections in immunocompromized, and debilitated patients, especially those in the intensive care units (ICUs). The most common presentation is pneumonia in mechanically ventilated patients in the ICUs (Montefour *et al*., 2008). Crude mortality rate of 30 ‒ 75% has been reported for *Acinetobacter* pneumonia in hospitalized patients and even more in ventilator assisted patients (Paul *et al*., 2007). Apart from pneumonia, wound infection, bacteremia, urinary tract infection, secondary meningitis, native-valve infective endocarditis, peritonitis, keratitis, and osteomyelitis have been reported globally (Peleg *et al*., 2008). Invasive procedures involving endotracheal tube, central venous catheter, urinary tract insertions, lumber puncture, myelography, ventriculography and ventriculoperitoneal shunt are the leading risk factors for infections. Mortality rate for central nervous system infection has been reported to be 20 to 27% in patients, in whom *A. baumannii* has been isolated from their cerebrospinal fluid (Seifert *et al*., 1995).

Acinetobacters can survive for ˃4 months in the environment, which is longer than 7 days survival period for *S. aureus* (Deitz *et al*., 1988). Because of this and aforementioned features, it has successfully involved in several outbreaks across the globe. In early 1980s, *A. baumannii* nosocomial outbreaks were described in South Europe, particularly in France, Germany, England, Netherlands, and Spain (Villegas and Hartstein, 2003; Fournier and Richet, 2006). The spread to Northern European countries like, Belgium and Germany has been linked with international transfer of colonized patients and airline travel (Peleg *et al*., 2006a). International *A. baumannii* clones known as European clones I, II and III have been reported in several European countries and also the United States (Nemec *et al*., 2004, van Dessel *et al*., 2004, Wroblewska *et al*., 2007). A data collected by National Nosocomial Surveillance Infection System from several hospitals in New York, USA from 1984 to 2003 on the prevalence of multidrug resistant *Acinetobacter* strains showed that the commonest manifestation was in ICU acquired pneumonia due to *A.* baumannii, which was found to be 4% in 1986 and 7% in 2003 (Gaynes and Edward, 2005). This substantial rise in United States was observed to have been contributed by the injured military personnel returning from war in Iraq and Afghanistan (Davis *et al*., 2005). Similar surveillance from 1997 to 2001 in South American countries like, Argentina, Colombia, Chile, and Brazil showed increase prevalence of MDR A. baumannii (Tognim *et al*., 2004). Back home in Nigeria, a study conducted by Iregbu et al. (2002) clearly revealed high prevalence of MDR *A. baumannii* found to be 50/58 (86.2%) in Lagos University Teaching Hospital (LUTH), Lagos. Also in a recent study conducted in the University College Hospital (UCH), Ibadan Nwadike et al. (2013) documented a prevalence of 11/14 (79.0%) for MDR *A. baumannii* specie over other species of Acinetobacters investigated.

The phenomena of emergence of MDR in this bacterium have also been traced to mutation in the drug target sites, acquisition of drug resistance genes, or emergence of new acquired mechanisms. The evolution of antibiotic resistance in Acinetobacters can be divided into two major eras: 1) before 1975, that marked the discovery of penicillin and awareness of this pathogen; and 2) after 1975, when there were substantial advances in invasive procedures in ICUs and discovery of powerful antibiotics. During this second period, new pattern of emergence has emerged and have been disseminated to many health care facilities. Currently, *Acinetobacter* infections are treated with aminoglycosides, cephalosporins (3rd and 4th generations), carbapenems, polymyxins, and Tigecycline either single or in combination and multidrug-, pandrug-, and extensively resistant *A. baumannii* have already emerged. A combined therapy of rifampin with carbapenems/polymyxins had given promising results but rifampin resistant strains have already been noticed. Alarmingly, there is paucity of information on the epidemiology and trends of antimicrobial resistance of *A. baumannii* from most African countries, including Nigeria.

This current study is centered on investigating the susceptibilities pattern of *A. baumannii* to spectrum of 34 antimicrobial agents belonging to 13 classes of antibiotics, some of which are not readily available in Nigeria. The results from this study will provide a scaffold for empiric prescription of antibiotics to patients with *A. baumannii* infections, as well as finding the current state of susceptibility of *A. baumannii* in southwest Nigeria.

**Materials and Methods:**

**Study Population:** Clinical specimens were collected from male and female patients attending 8 selected tertiary hospitals in southwest Nigeria. The samples were collected from microbiology laboratories of these various tertiary hospitals.

**Sample Collection:** The clinical specimens which include: mid-stream urine, wound swab, surgical swab, urethra swab, eye swab, blood and biopsy were collected from over 550 patients. The specimens collected were transported to pharmaceutical microbiology laboratory of University of Ibadan for standard biochemical analysis.


**Isolates identification:** All the isolates recovered were cultured on Eosin methylene blue (EMB) agar and MDR Leeds Acinetobacter medium (LAM). The identities of the isolates to species level were confirmed by standard biochemical methods using Oxoid Microbact™ Gram-negative identification system.

**Antimicrobial Susceptibility Test:** Antimicrobial susceptibility testing was performed by disk diffusion method on sensitivity test agar according to the Clinical and Laboratory Standards Institute guidelines (CLSI, 2010). A total of 34 antimicrobial agents from Oxoid Ltd (Fig. 1) were tested, consisting of 18 β-lactams/cephalosporins, 2 macrolides, 4 fluoroquinolones, 3 aminoglycosides, chloramphenicol, tetracycline, nitrofurantoin, nalidixic acid, trimethoprim-sulfamethoxazole, polymyxin B and colistin sulphate.

**Results:**

During the study period, a total of 72 clinical isolates of *A. baumannii* were recovered from 8 different tertiary hospitals (Table 1). The most common source of isolate derivation was from wound swab (20.8%) followed by surgical swab (18.1%), blood (16.7%). Least isolate derivation were from urethra swab and eye swab with 6.9% and 2.8% respectively.

The antimicrobial susceptibility profiles of *A. baumannii* isolates from these studied institutions are shown in Fig. 1. Amazingly, all theisolates were resistant to ≥14 antimicrobial agents tested, with 69 (95.8%) isolates resistant to 20-34 antimicrobial agents. All the isolates were resistant to amoxicillin, amoxicillin clavulanic acid, ampicillin, cefpodoxime, ceftazidime, ceftriaxone, cefuroxime, and cloxacillin. Significantly high rates of resistance were observed for erythromycin (98.6%); cephazolin (97.2%); aztreonam (93.1%); tetracycline (91.7%); cephalothin, trimethoprim-sulfamethoxazole (90.3%); kanamycin (88.5%); gentamicin, ticarcillin (86.1%); piperacillin, cefoxitin (87.5%), nitrofurantoin (81.9%); chloramphenicol (80.3%); ofloxacin (66.7%); and colistin (63.9%). High rates of carbapenem resistance were also recorded against meropenem (77.8%) and imipenem (56.9%). The least resistance was observed for azithromycin (37.9%); ciprofloxacin, polymyxin B (40.3%); and amikacin (43.1%).



**Table 1:** Distribution of *A. baumannii* isolates recovered from various clinical sources in this study.

|  |  |  |
| --- | --- | --- |
| **Sources/Sites of *A. baumannii* isolates** | **Number of isolates** | **Percentage (%) of isolates** |
| **Wound swab** | 15 | 20.8 |
| **Surgical swab** | 13 | 18.1 |
| **Blood** | 12 | 16.7 |
| **Biopsy** | 9 | 12.5 |
| **Urine** | 8 | 11.1 |
| **Burns** | 8 | 11.1 |
| **Urethra swab** | 5 | 6.9 |
| **Eye swab** | 2 | 2.8 |
| **Total** | 72 | 100.0 |

**Discussion:**

This current study identified these isolates to specie level using computer aided Oxoid MicrobactTM identification system. Antimicrobial resistance among *Acinetobacter* species has increased significantly in the past decades (Maragakis and Perl, 2008). The ability of *Acinetobacter* species to extensively resist antimicrobial agents may be explained in part by the organism’s relatively impermeable outer membrane, selective pressure, and environmental exposure to a large reservoir of resistance genes (Bonomo and Szabo, 2006).

Definitions of multidrug-resistant *Acinetobacter* species vary, referring to a wide array of genotypesand phenotypes (Falagas et al., 2006). Two of the most common definitions ofmultidrug resistance are carbapenem resistance or resistance to≥3 classes of antimicrobials (Falagas et al., 2006). This observation was made of our isolates as all the strains were resistance to ≥3 classes of antimicrobial agents investigated in this study. Strain thatdemonstrated resistance to all antimicrobial agents used in this study, includingpolymyxins, was also recorded. In this study all the strains exhibited resistance to ≥14 antimicrobial agents tested, with 95.8% showing resistant to 20-34 antimicrobial agents employed in this study. All (100%) strains were resistant to amoxicillin, ampicillin, amoxicillin-clavulanate, cefpodoxime, ceftazidime, ceftriaxone, cefuroxime, and cloxacillin used in this study (Fig. 1). In 1970s, *Acinetobacter* infections were treated with ampicillin, second generation cephalosporins, minocycline, colistin, carbenicillin and gentamicin (Iregbu et al., 2002). Today, most strains are resistant to ampicillin, cefotaxime, and chloramphenicol, with reports of 84% resistant to gentamicin in some institutions (Iregbu et al., 2002). This is consistent with the observation made in this study.

Among the class of penicillins used in this study as indicated by the black colour coded bars, all the strains (100%) were resistance to amoxicillin-clavulanate, ampicillin, and cloxacillin (Fig. 1). Similarly, remarkably high level of resistance was also recorded for ticarcillin (86.1%) and piperacillin (87.5%). This is comparable with results obtained by Ling et al., (2005) with resistance of 76% to ticarcillin and 78.9% to piperacillin.

Out of the two β-lactamase inhibitors used, amoxicillin-clavulanate did not improve the antimicrobial activity with all the isolates showing resistance. Similarly, relatively low level of susceptibility was also observed for ampicillin-sulbactam with resistance rate of 62.5%. This is in agreement with previous observation made by Higgins et al., (2004).

For the antibiotic class cephems indicated by the wine colour coded bars, all the isolates were resistance to cefuroxime the only second generation subclass of cephalosporin investigated. Similarly zero susceptibility rates were also recorded against the third generation subclass of cephalosporin, ceftazidime, ceftriaxone, and cefpodoxime. These observations were comparable to report made by Iregbu et al., (2002) against ceftriaxone and cefuroxime. For the first generation subclass, cephazolin and cephalothin, and subclass cephamycins, cefoxitin, significantly high resistance rates were noted. While 97.2% resistant rate was noticed for cephazolin, 90.3% was observed for cephalothin and 87.5% for cefoxitin. However, it is interesting to observe in this study, the emerging resistant pattern to cefepime. Cefepime a fourth generation subclass of cephalosporins has remained one of the most potent drugs against infections caused by *A. baumannii*. Amazingly, it is alarming to observe the relatively high level resistant of 66.7%, considering the relative low level of availability and use in these institutions. Generally, cephalosporins are β-lactam antibiotics with reportedly high antimicrobial activity and low toxicity. Increased resistance observed from *A. baumannii* isolates recovered from these institutions could partly be explained by high level production of extended-spectrum beta-lactamases (ESBLs) induced by selective pressure from broad-spectrum antimicrobial therapy. Apart from cefepime, which is not readily available across drug counters, the other subclasses of cephalosporins used in this investigation were found to be prevalently prescribed in these institutions (unpublished observation).

Carbapenems remain the antibiotic of choice to treat *A. baumannii* and other Gram-negative infections due to both a wider spectrum of antibacterial activity and less frequent side effects (Fonseca et al., 2013). However, their overuse and misuse have selected for nosocomial isolates presenting intrinsic and acquired multidrug resistance determinants (Kuo et al., 2012a). It has been considered that resistance against carbapenems is, in itself, sufficient to define an *A. baumannii* as highly resistant (Fonseca et al., 2013). The result in this study on the carbapenems utilized revealed a 77% resistance rate for meropenem. This value contrasted the 63% reported in South Africa by Kock et al., (2013), but in tandem with result documented for *A. baumannii* investigated by Fonseca et al., (2013) in Brazil. Similarly, high level of resistance (56.9%) as indicated by purple colour coded bar (Fig. 1) was recorded against imipenem. This in a way contradicts 91.3% observed by Ramoul et al., (2013) in Algeria health care centers. This is a probable indication of the emergence of carbapenem-resistance strains of *A. baumannii* in Nigeria like other parts of the world. Surveillance studies have shown that the percentage of carbapenem-resistant isolates gradually increased over the last ten years in Europe, North America, and Latin America (Peleg et al., 2008). In other countries such as Tunisia and South Africa (Poirel et al., 2008), China, Taiwan, Singapore, Hong Kong, Japan, South Korea (Mendes et al., 2009), and Australia (Peleg et al., 2006), numerous outbreaks of carbapenem-resistant strains have been reported.

Aminoglycosides are usually used in combination with another active antimicrobial agent. However, many MDR Acinetobacter isolates showing intermediate susceptibility has been noted for amikacin. In this study, amikacin with 43.1% resistance rate, showed better activity against *A. baumannii* than gentamicin (86.1%) and kanamycin with 88.9%. Similar finding was reported by Nemec and Maixnerová, **(**2004) with amikacin, gentamicin and kanamycin having similar trend of 47%, 87% and 93% resistance rates respectively.

Polymyxins are group of polycationic peptide antibiotics, exhibiting potent efficacy against most Gram-negative bacteria (Benedict and Langlykke, 1947; Stansly et al., 1947). Among all the five chemical compounds (A–E) of polymyxins, only polymyxin B and E (colistin) are used clinically. In this study, 40.3% of the strains were resistant to polymyxin B while 63.9% were resistant to colistin. This increase is suggestive of overuse. In a recent study conducted by Hannan et al., (2014), in Pakistan all the strains of *A. baumannii* investigated were susceptible to polymyxin B and resistant to colistin. Reports from multiple investigators have also illustrated a 100% susceptibility to extensively drug resistant (XDR) *A. baumannii* strains (Kuo et al., 2012b; Lim et al., 2011). Colistin resistance has been reported from various regions of the world. In Spain, colistin resistance was found to be 40.6% (Arroyo et al., 2009), and 12% in Kuwait (Al-Sweih et al., 2011). In a study reported by Chang et al., (2012), 10.4% colistin resistance was documented. In another similar study by Rodriguez et al., (2010), colistin resistance was found to be 7.1%. Although the frequency of colistin resistance is low globally in contrast to our findings, it has been substantiated through *in-vitro* experiment that the rate of development of resistance among *Acinetobacter* to colistin is rapid (Tan et al., 2007). Colistin is now used in the treatment of infections caused by MDR and XDR Gram-negative organisms such as *Pseudomonas* and *A. baumannii* due to its relatively low neurotoxicity and nephrotoxicity as compare to Polymyxin B.

Fluoroquinolones a subclass of quinolones are among the most widely used antibiotic in clinical practice and are highly effective against most Gram-negative species. Currently, multiple studies have shown a steady increase in the resistance to fluoroquinolones in *Acinetobacter* species clinical isolates and more concretely in *A. baumannii* with resistance rate higher than 75% (Hujer et al., 2009; Chopra et al., 2010). In contrast to our findings, fluoroquinolones seem more active in comparison with other classes of antibiotics used in this study against the strains of *A. baumannii* recovered from these institutions. While 66.7% was resistant to ofloxacin, 56.9% was recorded against sparfloxacin and 45.8% against norfloxacin. The least resistance was observed for ciprofloxacin with resistant rate of 40.3%. The gradual increase in resistance observed for fluoroquinolones in this study is suggestive of a possible overuse of these groups of antibiotics in these institutions. Also worthy of note is the significant high resistance recorded against the other classes of antibiotics used in this study. For erythromycin, 98.6% of isolates were found to be resistance, 93.1% were noted for aztreonam, while 91.7% were observed for tetracycline. Others such as trimethoprim-sulfamethoxazole, nitrofurantoin, chloramphenicol, and nalidixic acid, 90.3%, 81.9%, 80.6%, and 72.2% were documented. Amazingly, azithromycin a class of macrolides used against Gram-positive organisms was the most remarkably active antibiotics with susceptibility rate of 61.1%, suggestive of none usage of this antibiotic in the treatment of infections caused by MDR *A. baumannii* in these institutions.

**Conclusion:**

*A. baumannii* isolates from these institutions showed unacceptably high rates of resistance to multiplicity of antimicrobial agents, including those not readily available in Nigeria. To deal with the increasing antimicrobial resistance of *A. baumannii*, measures for controlling overuse and abuse of antibiotics should be instituted in these hospitals. Antibiotics should only be prescribed if an infection is highly suspected. Physicians should choose an older generation of antibiotic according to the antimicrobial susceptibility results and reserve the powerful newer antibiotics. If the culture results are shown to be negative and no sign of infection, antibiotic therapy should be discontinued.

**Acknowledgements:**

I am grateful to all the Medical Microbiology Laboratories of the various tertiary institutions where isolates used in this research was recovered. I appreciate all your efforts and assistance towards the realization of this work.

**Corresponding Author:**

Adeniyi BA

Department of Pharmaceutical Microbiology,

University of Ibadan, P.O. Box 22039, Orita U.I.,

Post office, Ibadan, Nigeria.

**E-mail**: [baadeniyi@yahoo.co.uk](mailto:baadeniyi@yahoo.co.uk)

Tel: +2348023451480.

**References**

1. Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in *Acinetobacter* species isolated from patients in Kuwait hospitals. *J. Chemother*. 2011; 23: 13-16.
2. Arroyo LA, Mateos I, González V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi-and pandrug-resistant clinical isolates of *Acinetobacter baumannii* group. *Antimicrob. Agents Chemother*. 2009; 53:1295-1296.
3. Benedict RG, Langlykke AF. Antibiotic activity of Bacillus polymyxa. *J Bacteriol.* 1947; 54: 24.
4. Bergogne-BereZin E, Towner KJ. *Acinetobacter* spp. as nosocomial pathogen: Microbiological, clinical and epidemiological features. *Clin. Microbiol. Rev*. 1996; 9:148-65.
5. Bonomo RA, Szabo D.Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa. Clin Infect Dis.* 2006; 43 (Suppl. 2): 49–56.
6. Brown S and Amyes SGB. OXA (beta)-lactamases in *Acinetobacter*: the story so far. *J. Antimicrob. Chemother.* 2006; 57: 1 – 3.
7. Chang KC, Lin MF, Lin NT, Wu WJ, Kuo HY, Lin TY, Yang TL, Chen YC, Liou ML. Clonal spread of multidrug-resistant *Acinetobacter baumannii* in eastern Taiwan. *J. Microbiol. Immunol. Infect*. 2012; 45: 37-42.
8. Chen TL, Wu RC, Shaio MF, Fung CP, Cho WL. Acquisition of a plasmid borne *bla*OXA-58 gene with an upstream IS*1008* insertion conferring a high level of carbapenem resistance to *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2008; 52: 2573-80.
9. Chopra S, Torres-Ortiz M, Hokama L. Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010; 65: 2598-601.
10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 20th informational supplement. 2010; Document M100 S20. Wayne, PA: 15.
11. Corvec S, Poirel L, Naas T. Drugeon H, Nordmann P. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene *bla*OXA-23 in *Acinetobacter baumannii. Antimicrob Agents Chemother*. 2007; 51:1530-3.
12. Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug resistant *Acinetobacter* extremity infections in soldiers. *Emerg. Infect. Dis*. 2005; 11: 1218-24.
13. Deitz JW, Goodrich JA, Brown WB. *Acinetobacter calcoaceticus* foot infection following to high pressure injection injury: *Foot ankle*. 1988; 8: 218-22.
14. Falagas ME, Karveli EA.The changing global epidemiology of *Acinetobacter baumannii* infections: a development with major public health implications. *Clin Microbiol Infect.* 2007b; 13:117-9.
15. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. *J Med Microbiol*. 2006; 55 (Pt 12):1615–1617.
16. Fonseca EL, Scheidegger E, Freitas FS, Cipriano R, Vicente ACP. Carbapenem-resistant *Acinetobacter baumannii* from Brazil: role of *carO* alleles expression and *bla*OXA-23 gene. *BMC Microbiology.* 2013; 13: 245.
17. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis. 2006; 42: 692-99.
18. Gaynes R, Edward JR. Overview of nosocomial infections caused by Gram-negative bacilli. *Clin. Infect. Dis*. 2005; 41: 848-54.
19. Hannan A, Khalid F, Arshad MU. In-vitro efficacy of polymyxin B with rifampin, colistin and doxycycline against extensively drug resistant *Acinetobacter baumannii*. *Afr. J. Microbiol. Res.* 2014; 8: 341-347.
20. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In Vitro Activities of the β Lactamase Inhibitors Clavulanic Acid, Sulbactam, and Tazobactam alone or in Combination with β-Lactams against Epidemiologically Characterized Multidrug Resistant *Acinetobacter baumannii* strains. *Antimicrob. Agents Chemother.* 2004; 48: 1586-1592.
21. Hujer KM, Hujer AM, Endimiani A. Rapid determination of quinolone resistance in Acinetobacter spp. J Clin Microbiol. 2009; 47:1436-42.
22. Iregbu KC, Ogunsola FT, Odugbemi TO. Infections caused by *Acinetobacter* species and their susceptibility to 14 antibiotics in Lagos University Teaching Hospital, Lagos. *West Afr. J. Med.* 2002; 21: 226-229.

### Kock MM, Bellomo AN, Storm N, Ehlers ME. Prevalence of carbapenem resistance genes in *Acinetobacter baumannii* isolated from clinical specimens obtained from an academic hospital in South Africa. *South Afr. J Infect Dis*. 2013; 28: 2312-0053.

1. Kuo HY, Chang KC, Kuo JW, Yueha HW, Liouf ML. Imipenem: a potent inducer of multidrug resistance in *Acinetobacter baumannii*. *Int J Antimicrob Agents*. 2012a; 39: 33-38.
2. Kuo SC, Chang SC, Wang HY, Lai JF, Chen, PC, Shiau YR, Huang IW, Lauderdale TL. Emergence of extensively drug-resistant *Acinetobacter baumannii* complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. *BMC Infect. Dis*. 2012b; 12:200.
3. Lee HY, Chen CL, Wang SB. Imipenem heteroresistance induced by imipenem in multidrug-resistant *Acinetobacter baumannii*: mechanism and clinical implications. *Int J Antimicrob Agents.* 2011; doi:10.1016/j.ijantimicag.2010.12.015.
4. Lim TP, Tan TY, Lee W, Sasikala S, Tan TT, Hsu LY, Kwa AL. *In vitro* activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant *Acinetobacter baumannii* in Singapore. *PLoS One*. 2011; 4:e18485.
5. Ling KWT, Ying CM, Lee CC, Liu ZK. Comparison of Antimicrobial Resistance of *Acinetobacter baumannii* Clinical Isolates from Shanghai and Hong Kong. *Med. Princ. Pract*. 2005; 14: 338–341.
6. Maragakis LL, Perl TM. *Acinetobacter baumannii:* Epidemiology, Antimicrobial Resistance, and Treatment Options. *Clin. Infect. Dis.* 2008; 46:1254–63.
7. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among *Acinetobacter* spp. in Asia-Pacific nations: report from the SENTRY surveillance program. *J Antimicrob Chemother*. 2009;63: 55-59.
8. Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin Mary. An emerging multidrug resistant pathogen in critical care. *Critical care Nurse*. 2008; 28: 15-25.
9. Nemec A, Dijkshoorn L, van der Reijden TJ. Long-term predominance of two pan-European clones among multi-resistant *Acinetobacter baumannii* strains in the Czech Republic. *J. Med. Microbiol*. 2004; 53: 147-53.
10. NemecA, Maixnerová M.Aminoglycoside resistance of *Acinetobacter baumannii* hospital strains in the Czech Republic. *Klin Mikrobiol Infekc Lek*. 2004;10:223-8.
11. Nwadike VU, Fayemiwo SA, Fowotade A, Bakare RA, Olusanya OO. Risk factors and outcome of *Acinetobacter* infection in the intensive care unit of a tertiary center in Oyo State, Nigeria. *Afr. J. Microbiol. Res.* 2013; 7: 1838-1844.
12. Paul S, Gregory D, Arjun S, Clinton M, Kimberly M, Ed H. Out break of multidrug resistant *Acinetobacter baumannii-calcoaceticus complex* infection in the US military health care system associated with military operation in Iraq. *Clin. Infect. Dis*. 2007; 44: 1577-82.
13. Peleg AY, Bell JM, Hofmeyr A, Wiese P. Inter-country transfer of gram negative organisms carrying the VIM-4 and OXA-58 carbapenem-hydrolyzing enzymes. *J. Antimicrob. Chemother*. 2006a; 57: 794-95.
14. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: Emergence of successful pathogen. *Clin. Microbiol. Rev*. 2008; 21: 538-82.
15. Poirel L, Mansour W, Bouallegue O, Nordmann P. Carbapenem-resistant *Acinetobacter baumannii* isolates from Tunisia producing the OXA-58-like carbapenem hydrolyzing oxacillinase OXA-97. *Antimicrob Agents Chemother*. 2008; 52: 1613-1617.
16. Poirel L, Nordmann P. Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene *bla*OXA-58 in *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2006; 50:1442-8.
17. Rajamohan G, Srinivasan VB, Gebreyes WA*.* Biocide-tolerant multidrug-resistant *Acinetobacter baumannii* clinical strains are associated with higher biofilms formation. *J. Hosp. Infect*. 2009; 73: 287–289.
18. Ramoul A, Hammami S, Dekhil M, Aimiri S, Slim A, Boubaker IB. Phenotypic and genotypic characterization of clinical multidrug resistant *Acinetobacter baumannii* from Algerian intensive care units. *Afr. J. Microbiol. Res.* 2013; 7: 868-874.
19. Rodriguez-Martinez JM, Nordmann P, Ronco E, Poirel L. Extended spectrum cephalosporinase in *Acinetobacter baumannii. Antimicrob Agents* *Chemother.* 2010; 54: 3484-3488.
20. Seifert H, Richter W, Pulverer G. Clinical and bacteriological features of relapsing shunt-associated meningitis due to *Acinetobacter baumannii*. *Eur. J. Clin. Microbiol. Infect. Dis*. 1995; 14; 130-134.
21. Stansly PG, Shepherd RG, White HJ. Polymyxin: a new chemotherapeutic agent. *Bull Johns Hopkins Hosp*. 1947; 81: 43–54.
22. Tan CH, Li J, Nation RL. Activity of colistin against hetero-resistant *Acinetobacter baumannii* and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. *Antimicrob. Agents Chemother*. 2007; 51: 3413-3415.
23. Tognim MC, Andrade SS, Silbert S, Gales AC, Jones RN, Sader HS. Resistance trends of *Acinetobacter* spp. in Latin America and characterization of international dissemination of multidrug- resistant strains: five years report of the SENTRY Antimicrobial surveillance Program. *Int. J. Infect. Dis*. 2004; 8: 284-91.
24. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of *Acinetobacter baumannii* by detection of the *bla*OXA-51- like carbapenemase gene intrinsic to this species. *J. Clin Microbiol*. 2006; 44: 2974-76.
25. van Dessel H, Dijkshoorn L, van der Reijden TJ, Bakker N, van den Broek P. Identification of a new geographically widespread multidrug-resistant *Acinetobacter baumannii* clone from European hospitals. *Res. Microbiol*. 2004; 155: 105-12.
26. Villegas MV, Hartstein AI. *Acinetobacter* outbreaks, 1977-2000. *Infect. Control Hosp. Epidemiol.* 2003; 24: 283-95.
27. Weisburg WG, Barns SM, Pelletier DA, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. *J. Bacteriol*. 1991; 173: 697-703.
28. Wroblewska MM, Towner KJ, Marchel H, Luczak M. Emergence and spread of carbapenem-resistant strains of *Acinetobacter baumannii* in a tertiary health care hospital in Poland. *Clin. Microbiol. Infect*. 2007; 13: 490-96.

10/28/2014